Cytokinetics (CYTK) director awarded new stock and option grants
Rhea-AI Filing Summary
Cytokinetics Inc. director Wendell Wierenga reported equity compensation awards. On May 27, 2026, he received 2,851 shares of Common Stock as a grant at no cash cost, increasing his direct holdings to 35,488 shares.
He was also granted a Non-Qualified Stock Option for 4,301 shares of Common Stock at an exercise price of $77.15 per share. This option is scheduled to become exercisable starting June 27, 2026 and expires on May 26, 2036, adding to his long-term incentive position with the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,851 shares
Net Buy
2 txns
Insider
WIERENGA WENDELL
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (Right to Buy) | 4,301 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 2,851 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 4,301 shares (Direct);
Common Stock — 35,488 shares (Direct)
Key Figures
Common stock grant: 2,851 shares
Option grant shares: 4,301 shares
Option exercise price: $77.15 per share
+3 more
6 metrics
Common stock grant
2,851 shares
Equity award on May 27, 2026
Option grant shares
4,301 shares
Non-Qualified Stock Option awarded May 27, 2026
Option exercise price
$77.15 per share
Non-Qualified Stock Option for 4,301 shares
Shares owned after grant
35,488 shares
Director’s direct Common Stock holdings after award
Option expiration date
May 26, 2036
Non-Qualified Stock Option term end
Option exercisable date
June 27, 2026
Earliest exercise date for 4,301-share option
Key Terms
Non-Qualified Stock Option (Right to Buy), Common Stock, grant/award acquisition, Form 4
4 terms
Non-Qualified Stock Option (Right to Buy) financial
"Security title listed as "Non-Qualified Stock Option (Right to Buy)""
Common Stock financial
"Security title for the 2,851-share grant is "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
grant/award acquisition financial
"transaction_action field describes the event as "grant/award acquisition""
Form 4 regulatory
"Insider transaction data is reported in a Form 4 filing"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did CYTOKINETICS (CYTK) disclose for Wendell Wierenga?
Cytokinetics reported that director Wendell Wierenga received equity compensation. He was granted 2,851 shares of Common Stock and a stock option for 4,301 shares, both recorded on May 27, 2026 as direct ownership awards.
What are the key terms of Wendell Wierenga’s new CYTOKINETICS (CYTK) stock option?
Wendell Wierenga received a Non-Qualified Stock Option covering 4,301 shares of Cytokinetics Common Stock at an exercise price of $77.15 per share. The option becomes exercisable starting June 27, 2026 and expires on May 26, 2036.
Is the CYTOKINETICS (CYTK) Form 4 transaction a purchase or a grant?
The Form 4 shows grant or award acquisitions rather than open-market purchases. Both the 2,851-share Common Stock award and the 4,301-share stock option were reported with code A, indicating compensation-related grants at no cash purchase price.
Does the CYTOKINETICS (CYTK) filing show any insider stock sales?
The disclosed Form 4 for Wendell Wierenga does not report any stock sales. It lists two acquisition transactions, both coded as grants or awards: one in Common Stock and one in a Non-Qualified Stock Option, with no dispositions reported.